2020
Genomic profiling of breast cancer brain metastases reveals targetable alterations.
Kabraji S, Spurr L, Hughes M, Li Y, Leone J, Garrido-Castro A, Barroso-Sousa R, Files J, Kirkner G, Johnson B, Winer E, Cherniack A, Lin N. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Journal Of Clinical Oncology 2020, 38: 2525-2525. DOI: 10.1200/jco.2020.38.15_suppl.2525.Peer-Reviewed Original ResearchBreast cancer brain metastasesTumor mutation burdenCancer brain metastasesBrain metastasesTargetable alterationsGenomic alterationsDana-Farber Cancer InstituteTwo-sided Fisher's exact testPIK3CA/PTENActionable genomic alterationsFisher's exact testNumber alterationsTwo-sided MannWhitney U testPrimary tumorMetastatic tumorsMutation burdenERBB2 amplificationCancer InstituteMultiple comparison correctionCancer-related genesExact testCopy number alterationsGenomic profilingU test
2019
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3: 1-9. PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/po.19.00087.Peer-Reviewed Original ResearchMetastatic breast cancerEligible patientsBreast cancerExact testHER2-negative breast cancerOngoing phase II trialGenomic profilingPhase II trialProportion of patientsComprehensive genomic profilingRoutine clinical practiceFisher's exact testGenomic tumor profilingArchived tissue samplesII trialMedian timeTRIAL REGISTRATIONTrial participationClinical trialsSpecific genomic changesClinical impactGenomic testing resultsRare subsetPatientsClinical practiceGenomic landscape of de novo stage IV breast cancer.
Garrido-Castro A, Spurr L, Hughes M, Li Y, Cherniack A, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Files J, Kumari P, Cerami E, Krop I, MacConaill L, Lindeman N, Rollins B, Johnson B, Wagle N, Winer E, Dillon D, Lin N. Genomic landscape of de novo stage IV breast cancer. Journal Of Clinical Oncology 2019, 37: 1022-1022. DOI: 10.1200/jco.2019.37.15_suppl.1022.Peer-Reviewed Original ResearchDe novo stage IV breast cancerRecurrent metastatic breast cancerStage IV breast cancerBreast cancerMetastatic tumorsMHC class II expressionMetastatic breast cancerPoor overall survivalClass II expressionFisher's exact testEpithelial-mesenchymal transitionPrimary TNBCCopy number variationsOverall survivalMetastatic sitesCCND1 amplificationImmune escapePotential resistance mechanismsDistinct genomic profilesMetastatic driversMetastatic samplesTreatment selectionExact testMetastatic potentialGenomic profiling
2017
Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
Garrido-Castro AC, Winer EP. Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy? Journal Of The National Cancer Institute 2017, 109: djw316. PMID: 28376163, DOI: 10.1093/jnci/djw316.Peer-Reviewed Original ResearchConceptsPositive early breast cancerEarly breast cancerLocoregional therapyBreast cancerGenomic profilingTherapyCancer